Blueprint Medicines Corporation (BPMC)
Automate Your Wheel Strategy on BPMC
With Tiblio's Option Bot, you can configure your own wheel strategy including BPMC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BPMC
- Rev/Share 8.8384
- Book/Share 5.3794
- PB 23.7554
- Debt/Equity 0.3588
- CurrentRatio 2.8017
- ROIC -0.1759
- MktCap 8252959338.0
- FreeCF/Share -2.3728
- PFCF -54.6883
- PE -52.1893
- Debt/Assets 0.1027
- DivYield 0
- ROE -0.4889
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BPMC | Wedbush | Outperform | Neutral | -- | $129 | June 2, 2025 |
| Resumed | BPMC | Morgan Stanley | -- | Equal Weight | -- | $100 | March 20, 2025 |
| Initiation | BPMC | Wolfe Research | -- | Outperform | -- | -- | March 18, 2025 |
| Initiation | BPMC | Jefferies | -- | Buy | -- | $135 | March 17, 2025 |
| Initiation | BPMC | Scotiabank | -- | Sector Outperform | -- | $150 | March 7, 2025 |
News
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY).
Read More
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Blueprint will receive $129.00 per share, representing an equity value of approximately $9.
Read More
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation (NASDAQ: BPMC) to Sanofi is fair to Blueprint shareholders. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achie.
Read More
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
Published: June 02, 2025 by: Barrons
Sentiment: Positive
The deal announced Monday is Sanofi's third of the year so far.
Read More
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Published: June 02, 2025 by: WSJ
Sentiment: Positive
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Read More
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Conference Call Participants Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Yee - Jefferies Colleen Kusy - Baird Derek Archila - Wells Fargo Brian Cheng - JPMorgan Reni Benjamin - Citizens Ami Fadia - Needham David Dai - …
Read More
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.
Read More
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.
Read More
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President and Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christina Rossi - Chief Operating Officer Conference Call Participants Brad Canino - Stifel Salveen Richter - Goldman Sachs Michael Schmidt - Guggenheim Brian Cheng - J.P. Morgan Derek Archila - Wells Fargo Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Ulz - Morgan Stanley David Dai - …
Read More
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
-- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass. …
Read More
About Blueprint Medicines Corporation (BPMC)
- IPO Date 2015-04-30
- Website https://www.blueprintmedicines.com
- Industry Biotechnology
- CEO Ms. Kathryn Haviland M.B.A.
- Employees 682